Loading stock data…
Lexicon Pharmaceuticals, Inc. (LXRX)
$2.64+0.09 (+3.53%)
After Hours$2.65+0.01 (+0.22%)· Last close Jun 29
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lexicon Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.64 with a market capitalization of $893M. Wall Street consensus targets $3.77 (5 analysts), implying a +42.8% move over the next 12 months. The stock is currently near its 52-week high of $2.67, remaining 69.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $21.10M↑ | $5.49M↓ | $14.18M↓ | $28.87M↑ | $1.26M |
| Gross Profit | $20.99M↑ | $5.29M↓ | $14.17M↓ | $28.83M↑ | $1.23M |
| Operating Income | -$996,000↑ | -$14.78M↓ | -$12.19M↓ | $3.74M↑ | -$25.68M |
| Net Income | -$1.04M↑ | -$15.53M↓ | -$12.77M↓ | $3.25M↑ | -$25.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small mole...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$892.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.86%
Volume
Today's trading volume
4.62M
Recent News
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?
Is LXRX a good stock to buy? We came across a bullish thesis on Lexicon Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on LXRX. Lexicon Pharmaceuticals, Inc.’s share was trading at $1.8800 as of June 9th. LXRX’s trailing P/E was 3.74 according to Yahoo Finance. Lexicon Pharmaceuticals is a […]
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates
Lexicon Pharmaceuticals comes into focus today with no changes to its existing price targets, which keeps the current analyst framework firmly in place. With no fresh commentary to reshape the story, you are essentially looking at a stable, unchanged view from the analyst community. Read on to see how to track these kinds of quiet updates so you can stay aligned with the evolving Lexicon Pharmaceuticals narrative over time. Stay updated as the Fair Value for Lexicon Pharmaceuticals shifts by...
Lexicon (LXRX) Q1 2026 Earnings Transcript
Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director; Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer; and Scott Coiante, Senior Vice President and Chief Financial Officer. This morning, Lexicon issued a press release announcing our financial results for the first quarter of 2026, which is available on our website at www.lexpharma.com and through our SEC filings.
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 11, 2026, Citi raised the firm’s price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating following the company’s Q1 2026 earnings report. On May 7, 2026, Lexicon Pharmaceuticals, Inc. […]